

# Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast Cancer

Yalcin S<sup>1\*</sup> and Gunduz U<sup>2</sup>

<sup>1</sup>Department of Molecular Biology and Genetics, Faculty of Science and Art, Ahi Evran University, Kirsehir, Turkey

<sup>2</sup>Department of Biology, Faculty of Science and Art, Middle East Technical University, Ankara, Turkey

## Abstract

Nanoparticle-based targeted drug delivery is a successful strategy to overcome the side effect of chemotherapy. Nanoparticles based drug delivery systems that have been designed to enhance delivery of therapeutics to tumors, are a novel approach. Nanoparticles have reactive surface that can be readily modified with biocompatible coatings and loaded with therapeutic agents (miRNA, siRNA, antibody, anti-cancer drug etc.). MicroRNAs (miRNAs or miRs) are short non-coding RNAs which posttranscriptionally regulate growth, differentiation, apoptosis, motility, and malignant transformation. In addition, some miRNAs have been classified as proto-oncogenes. The levels of changed miRNA expression play significant role in the initiation of many diseases, including cancer, especially tumor progression and metastasis. Further studies, miRNA conjugation to drug carrier systems is used to target to cancer cells. In this review, we focus on miRNA carrier nanoparticles, and summarize novel advances about their use in drug resistance breast cancer therapy.

**Keywords:** miRNA; Magnetic nanoparticles; Breast cancer; Drug resistance

## Introduction

Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death in women worldwide [1]. Surgery combined with chemotherapy is currently the most effective strategy for breast cancer therapy. However, most treatments are unsuccessful due to secondary recurrence, metastasis, and drug resistance [2]. Development of new therapies will be important to enhance the clinical outcome of breast cancer [3]. While several new therapeutic agents have been approved for the treatment of breast cancer [4,5], their ability to prolong life has been limited due to the rapid development of resistance [6]. A promising strategy that utilizes the same principle is miRNA-based therapeutics, as a single miRNA can have multiple targets in both the tumor cells themselves and the tumor microenvironment [7-10]. MicroRNAs (miRNAs) are single-stranded, small (22 nucleotide-long), and evolutionarily protected non-protein-coding RNAs [8,11]. Current evidence indicates that miRNAs play critical regulatory roles in cell proliferation, cell death, apoptosis, immune response, cell cycle, senescence, invasion, metastasis, and angiogenesis [12-18]. MiRNAs can regulate hundreds of target genes and control signaling pathways [19,20]. However, their unsuccessfully delivery at tumor area cause off-target effects [21]. Nanoparticle based targeted delivery of miRNAs to specific their tumor side and cells are novel and alternative approaches in cancer therapy. We summarize polymer-functionalized nanoparticles as miRNA carrier that can potentially be applied to deliver miRNA as therapeutics to overcome drug resistance in breast cancer.

## miRNAs in Drug Resistance Breast Cancer

Novel expanded miRNA families have been also discovered in breast cancer cell lines and human breast tissue samples. Increasing evidence suggests that miRNAs are involved in the development of resistant breast cancers through the regulation of estrogen resistance, apoptosis, drug transporters, epithelial mesenchymal transition (EMT), and cancer stem cells (CSCs). MiRNAs based microarrays and new generation of sequencing technologies have been reported on the association with breast cancer (Figure 1). For example, disturbance

of miRNA-210 functions may contribute to tumor aggressiveness and poor prognosis [22,23], while miR-355 inhibits tumor [24,25]. In breast cancer cells, silencing of miR-21 [26-30] caused the inhibition of cell proliferation, the downregulation of Bcl-2 and the induction of apoptosis *in vitro* and *in vivo* models [29]. Recent studies have demonstrated the role of miRNAs in the regulation of the Bcl-2 family of proteins. Bcl-2 proteins are important regulators of apoptosis. Studies show that Bcl-2 is regulated by miR-34a, miR-21, miR-203, miR-143, and miR-16 [31-51].

Approximately 90% of chemotherapy failures are due to drug resistance [52]. Chemotherapeutic agents, such as etoposide, doxorubicin, paclitaxel, topotecan, and 5-fluorouracil, are used to early and locally advanced breast cancers, but many patients receiving chemotherapy can develop a resistance. Most of studies have demonstrated that dysregulation of miRNAs have a key role in drug resistance [53]. The overexpression of ATP-binding cassette (ABC) drug transporters is an important reason for chemoresistance [54]. Pgp/MDR1 has important role as multiple drug resistance (MDR) transporters in drug disposition and distribution. Transcriptional regulation of MDR1 gene expression in drug resistance breast cancer cells by miRNAs has been reported in several studies. Polymorphisms of miR-24 miRNA binding site in the dihydrofolate reductase gene contribute to methotrexate resistance [55]. Zhu et al. demonstrated that the overexpression of miR-27a and miR-451 are involved in the development MDR in cancer cells [56]. Overexpression of miR-221 and miR-222 contribute to tamoxifen resistance in negative regulation

**\*Corresponding author:** Serap Yalcin, Department of Molecular Biology and Genetics, Faculty of Science and Art, Ahi Evran University, Kirsehir, Turkey, Tel: 90 386 280 42 00; E-mail: [syalcin@ahievran.edu.tr](mailto:syalcin@ahievran.edu.tr)

**Received** December 05, 2016; **Accepted** December 22, 2016; **Published** December 27, 2016

**Citation:** Yalcin S, Gunduz U (2016) Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast Cancer. J Nanomed Nanotechnol 7: 414. doi: 10.4172/2157-7439.1000414

**Copyright:** © 2016 Yalcin S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

of ER $\alpha$ , but silencing of miR-221 and/or miR-222 regulates ER $\alpha$  expression and tamoxifen sensitivity [57]. MiRNAs expression can also be used both as a potential therapeutic agent and a prognostic biomarker in drug resistant cancer cells [58].

Zhao et al., [59] investigated the effects of miR-21 on paclitaxel-resistance in human breast cancer MCF-7/PR and SKBR-3/PR cells. They found that the expression levels of MDR1, BCRP, MRP1, Bcl-2/Bax and miR-21 in MCF-7/PR and SKBR-3/PR cells were significantly higher than in parental MCF-7 and SKBR-3 cells. The protein levels of P-gp, Bcl-2 were found to be up-regulated, and Bax was down-regulated compared to the parental cells.

Doxorubicin, an anthracycline antibiotic, is a commonly used anticancer agent in many cancer types and its most serious side effect is heart damage [60]. MiRNA-134 has been reported to be down-regulated in doxorubicin-resistant MCF-7/ADR cell lines by Lu et al. Moreover, MCF-7/ADR cells were transfected with miR-134 mimics.

The results were supported with MTT assay that the cell proliferation was inhibited. They demonstrated to trigger apoptotic processes after transfection. The expression levels of ABC-C1 was upregulated in doxorubicin-resistant MCF-7/ADR cell lines [61]. Various studies indicated that upregulation of miR-451 expression levels down regulated the expression of MDR1 in the doxorubicin-resistant breast cancer cells [62]. In another study, miR-200c expression level was found to be downregulated in drug resistant MCF-7 cells when compared to drug sensitive MCF-7 cells. After transfected with miR-200c mimics, its upregulation may enhance the chemosensitivity to epirubicin in breast cancer cells [63-87]. Different miRNAs and target genes have been reported in drug resistance breast cancer cells as enlisted in Table 1 above.

### miRNAs and Nanoparticle Delivery Systems

The use of nanotechnology for drug delivery is successful strategy to enhance the delivery of therapeutics to tumors. This technology has contributed to development of nano-scale particles that can be used different materials including polymeric, dendrimeric, and magnetic nanoparticles (MNPs) [88]. The primary goal of targeted drug delivery is to carry therapeutics agents loaded nanoparticles to targeted tissues and to reduce nonspecific drug toxicity in normal tissues. The most important characteristics for successfully synthesized nanoparticle-mediated drug delivery systems are stability, the high loading capacity of nanoparticles, size, and the flexibility to carry therapeutics [89-91].

Magnetic nanoparticles (MNPs) have significant advantages in medicine as they can be targeted in the presence of a magnetic field. The use of anticancer agents is critical in chemotherapy. Chemotherapeutic agents that also arrive throughout the blood circulation to non-targeted systems can cause toxicity in healthy tissues and organs. Hence, development of anticancer agent loaded/conjugated MNP delivery systems can decrease the toxicity and non-selectivity of anticancer drugs [92]. These magnetic based delivery systems will also increase the agent efficiency and drug circulation time. Additionally, it has been reported that MNP had been found to be safe in vivo and in vitro studies such as MNPs did not affect liver enzyme levels in the long term and also did not induce oxidative stress in rats [93-96].

Synthetic and natural polymers have been used to coat surface of nanoparticles such as dextran, poly (aniline), poly (ethylene glycol), and polyesters, such as poly (lactic acid) and poly (hydroxybutyrate). The surfaces of nanoparticles have been modified with different approaches to bind molecules and to enhance delivery. For example, when the surface of the nanoparticles has been modified with carboxyl and amine groups, the nanoparticles can be conjugated easily with proteins, drugs, si-/miRNA, antibodies, carbohydrates, etc. [97].

MiRNAs play key role as both oncogenes and tumor suppressors [98,99] and they have therapeutics potential in cancer treatment. However, its non-effective delivery mechanism includes some limitations [100]. Free miRNAs are not stable and have a very short half-life because of their degradation by nucleases in blood, serum and other body fluids or tissues [101]. Therefore, an effective miRNA carrier systems have been required for efficiently delivering these therapeutics into cancer cells [102,103] (Figure 2). A different carriers that exhibits high stability and delivery efficiency, has been designed for miRNA delivery in breast cancer treatment (Table 2). When miRNAs are attached to the surface of nanoparticles, the efficacy of miRNA conjugated nanoparticles is more than free miRNA [104]. In recent years, down regulation of the expression of a tumor suppressive miRNA with nanoparticle based delivery has been reported to decrease




Figure 1: miRNAs in breast.

miRNAs	Target Gene	Drug	Cell lines	Ref
miR-139-5p	<i>Notch1</i>	Docetaxel	MCF7, MCF7/Docetaxel	[64]
miR-125a-3p	<i>BRCA1</i>	Docetaxel	MDA-MB-468/Docetaxel, MCF-7/Docetaxel, MDA-MB-468, MCF-7	[65]
miR-302a, miR-302b, miR-302c, and miR-302d	<i>BCRP</i>	Mitoxantrone	Mitoxantrone (MX)-resistant MCF-7 (MCF-7/MX)	[66]
miR-29a	<i>PTEN and GSK3β</i>	Adriamycin	ADR-resistant MCF-7 breast cancer cell subline (MCF-7/ADR)	[67]
miR-10b	<i>HDAC4</i>	Tamoxifen	Tamoxifen-resistance MCF-7	[68]
miR-155	<i>SOCS6-STAT3</i>	Tamoxifen	Tamoxifen sensitive and resistant MCF-7 and SKBR3 cells	[69]
miR-134	<i>ABCC1</i>	Doxorubicin	Doxorubicin- resistant and Doxorubicin-sensitive breast cancer samples	[61]
miR-193b	<i>MCL-1</i>	Doxorubicin	Doxorubicin- resistant and Doxorubicin-sensitive breast cancer samples	[70]
miR-125b	<i>Mcl-1</i>	Doxorubicin	Doxorubicin- resistant and Doxorubicin-sensitive breast cancer samples	[71]
miR-489	<i>SPIN-1</i>	Adriamycin	MCF-7, MDA-MB-231, MDA-MB-468, T47D, MCF-7/ADM (resistant to adriamycin) and drug-resistant tissues	[72]
miR-451	<i>Bcl-2</i>	Paclitaxel	Paclitaxel- resistant breast cancer samples	[73]
miR-141	<i>EIF4E</i>	Docetaxel	Docetaxel-resistant cells (MCF-7/DTX and MDA-MB-231/DTX) and Docetaxel-sensitive cells (MCF-7 and MDA-MB-231)	[74]
miR-217	<i>PTEN</i>	Tamoxifen, Etoposide, Lapatinib	MCF-7 and SKBR-3	[75]
miR-181b	<i>Bim</i>	Doxorubicin	Doxorubicin (DOX)-resistant T-47D cells (T-47D-R) and sensitive T-47D	[76]
miR-129-3p	<i>CP110</i>	Docetaxel	MDA-MB-231/Doc and MDA-MB-231	[77]
miR-873	<i>CDK-3</i>	Tamoxifen	Tamoxifen-resistant cells (MCF-7/TamR) and MCF-7/S	[78]
miR-125b	<i>Sema4C</i>	Paclitaxel	Paclitaxel-resistant (PR) breast cancer cells	[79]
miR-218	<i>Survivin</i>	Taxol and doxorubicin	Resistant MCF-7 and Cal51 cells	[80]
miR133a	<i>UCP-2</i>	Doxorubicin	Doxorubicin resistant MCF-7 and parental cell line MCF-7	[81]
miR-224-3p	<i>FUT4</i>	Adriamycin	Adriamycin-resistant MCF-7/ADR and T47D/ADR	[82]
miR-3646	<i>GSK-3β</i>	Docetaxel	MDA-MB-231/Doc MCF-7/Doc, MDA-MB-231/S and MCF-7/S	[83]
MiR-487a	<i>ABCG2</i>	Mitoxantrone	Mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX)	[84]
miR-221/222	<i>p27kip1</i>	Tamoxifen	Tamoxifen-sensitive and Tamoxifen-resistant MCF-7 cells.	[85]
miR-326	<i>ABCC1</i>	VP-16 and mitoxantrone	VP-16-resistant MCF-7 (MCF-7/VP), mitoxantrone-resistant MCF-7 (MCF-7/MX100) and MCF-7	[86]
miR-451	<i>ABCB1</i>	Doxorubicin	DOX-resistant MCF-7 cells (MCF-7/DOX) and MCF-7	[87]

Table 1: The list of miRNAs and target genes in drug resistance breast cancer cells.




Figure 2: Mechanism of miRNA loaded/attached nanoparticle systems in cancer cells.

miRNAs	Nanoparticles	Breast Cancer Cell line	Ref
miR-145	Polysorbitol-mediated transporter (PSMT)	MCF-7	[114]
miR-34a	Hyaluronic acid-chitosan nanoparticles	MDA-MB-231	[115]
miR-145	Chitosan polyplex nanoparticles	MCF-7	[110]
miR-34a	PEGylated-thymoquinone-nanoparticle	MCF-7	[116]
miR-542-3p	Hyaluronic acid-coated PEI-PLGA nanoparticles	MDA-MB-231 and MCF-7	[117]
miR-145	Gold nanoparticle (Au-NPs)	MCF-7	[118]
miR-125a-5p	Lipid nanoparticles	21MT-1 and MCF-10A	[119]
miR-10b	Polylysine Nanoparticles	MDA-MB-231	[120]
miR-21	Poly (ethylene glycol) conjugated poly (lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NPs)	MDA-MB-231 and SKBR3	[113]
miR-21 and miR10b	PLGA-b-PEG polymer NPs	MDA-MB- 231-Fluc-eGFP, mouse TNBC tumor xenograft model	[121]
miR-10b	Magnetic nanoparticles	MDA-MB-231-luc-D3H2LN	[122]
miR-129-5p	Poly(ethylene glycol)-b-poly(L-lysine)-b-poly (L-cysteine) (LCss) polypeptide nanoparticles	DOX-resistant MCF-7/ADR cells	[123]
miR-21, miR-145, and miR-9	Polyethyleneimine-modified MNPs	MCF-7	[124]
miR-let7a	Chitosan/Poly(c-Glutamic Acid)	MDA-MB231 and MCF-7	[111]
miR-21	Polyethylenimine (PEI)/poly (sodium 4-styrenesulfonates) (PSS)/graphene oxide (GO)	MCF-7/ADR	[112]

**Table 2:** Summary of current studies on the nanoparticle based miRNAs carriers in breast cancer cell line/in vivo model.

tumor growth in pre-clinical models [105-108]. Jin et al., demonstrated that polylysine-anti-mir-10b nanoparticle complex has inhibitory effect against breast cancer cells [109].

MiR-145, a tumor suppressor miRNA, is down regulated in cancer and can be introduced as a therapeutic agent in various cancers, including breast cancer. MiR-145 plasmid was transfected into MCF-7 cells by chitosan polyplex nanoparticles. Chitosan polyplex nanoparticles diminished the proliferation of MCF-7 cells by approximately 30% [110]. In another study, chitosan-PGA complex was conjugated with QD-miRNA let-7a-gold nanoparticles for delivery to MCF-7, MDA-MB231 breast cancer cells as model, showing its application potential in biomedicine [111]. MiRNA-21 overexpression related to the development multiple drug resistance in breast cancer. The polyethylenimine (PEI)/poly (sodium 4-styrenesulfonates) (PSS)/graphene oxide (GO) has been designed as carrier for Adriamycin (ADR) and anti-miR-21. This strategy is the developing multifunctional nanocomplex to overcome MDR, might represent a promising novel therapeutic approach for the treatment of breast cancer [112]. Additionally, orlistat and antisense miR-21 loaded poly(ethylene glycol)-conjugated poly(lactic-co-glycolic acid) nanoparticles enhanced apoptotic effect compared with independent doxorubicin, anti-miR-21-loaded NPs, orlistat-loaded NPs or free orlistat treatments in MDA-MB-231, SKBR-3 and normal breast fibroblast cells [113-123]. Table 2 summarizes currently studies on nanoparticles as carriers for miRNA in breast cancer cells.

Recently published findings by Yu et al. [124] demonstrate that miR-21, miR-9, and miR-145 were combined with PEI-modified magnetic nanoparticles. Their research suggests that in nude mice, the volume and weight of tumors decreased to just 58 % of that in the control.

The hyaluronic acid /protamine sulfate nanocapsules have been used to deliver miR-34a into triple negative breast cancer cells or tissues. The delivery of miR-34a induced apoptosis and cell death, reduced migration, proliferation of breast cancer cells via targeting CD44 and Notch-1- signaling pathways [125]. In a similar study, doxorubicin and miR-34a loaded chitosan nanoparticles were delivered into breast cancer cells to increase therapeutic effects of drug [115,126].

## Conclusion

miRNA could be a promising strategy for drug resistance breast cancer therapy. Clear evidences are given by the recent reports that miRNA and nanoparticles are beneficial in inhibiting the tumor growth. Various nanocarriers have been developed to deliver miRNA however these nanocarriers have limitations. The ideal nanoparticle delivery system should protect the miRNA from the RNases and efficiently deliver to tumor cells. Efficient targeting and release of miRNAs using magnetic nanoparticles can reduce the required therapeutic dosage and cellular toxicity. In the future, miRNA conjugated magnetic nanoparticles will achieve a maximum effect of targeted therapy for treating drug resistant tumors. Therefore, further experiments will be needed on the interactions between the nanoparticle based delivery of miRNAs and drug-resistant cells, there has been very little written research on this point.

## References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. *CA Cancer J Clin* 61: 69-90.
- Antoon JW, White MD, Slaughter EM (2011) Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. *Cancer Biology and Therapy* 11: 678-689.
- Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. *J Clin Oncol* 2: 1102-1109.
- Dayyani F, Gallick GE, Logothetis CJ, Corn PG (2011) Novel therapies for metastatic castrate-resistant prostate cancer. *Journal of the National Cancer Institute* 103: 1665-1675.
- Thoreson GR, Gayed BA, Chung PH, Raj GV (2014) Emerging therapies in castration resistant prostate cancer. *The Canadian journal of Urology* 21: 98-105.
- Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, et al. (2013) Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. *Cancer Discov* 3: 849-861.
- Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. *Cancer research* 70: 7027-7030.
- Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297.
- Suzuki HI, Katsura A, Matsuyama H, Miyazono K (2014) MicroRNA regulons in tumor microenvironment. *Oncogene* 34: 3085-3094.



10. Tong AW, Nemunaitis J (2008) Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? *Cancer Gene Ther* 15: 341-55.
11. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5: 522-31.
12. Negrini M, Calin GA (2008) Breast cancer metastasis: a microRNA story. *Breast Cancer Res* 10: 203.
13. O'Day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. *Breast Cancer Res* 12: 201.
14. Singh R, Mo YY (2013) Role of microRNAs in breast cancer. *Cancer Biol Ther* 14: 201-212.
15. McGuire A, Brown JA, Kerin MJ (2015) Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. *Cancer Metastasis Rev* 34: 145-55.
16. Cortes-Sempere M, Ibanez de Caceres I (2011) microRNAs as novel epigenetic biomarkers for human cancer. *Clinical and Translational Oncology* 13: 357-362.
17. Goh JN, Loo SY, Datta A, Siveen KS, Yap WN et al. (2016) microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. *Biol Rev Camb Philos Soc* 91: 409-428.
18. Muluhngwi P, Klinge CM (2015) Roles for miRNAs in endocrine resistance in breast cancer. *Endocr Relat Cancer* 22: R279-300.
19. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 6: 259-69.
20. Kunjinty PR, Schnittert J, Storm G, Prakash J (2016) MicroRNA Targeting to Modulate Tumor Microenvironment. *Front Oncol* 6: 3.
21. Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, et al. (2016) miRNA nanotherapeutics for cancer. *Drug Discov S* 1359-6446.
22. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, et al. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. *Clin Cancer Res* 18: 5972-5982.
23. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, et al. (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. *Proc Natl Acad Sci U SA* 109: 3024-3029.
24. Hongay CF, Grisafi PL, Galitski T, Fink GR (2006) Antisense transcription controls cell fate in *Saccharomyces cerevisiae*. *Cell* 127: 735-745.
25. Wu X, Zeng R, Wu S, Zhong J, Yang L, et al. (2015) Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels. *Gene* 557: 195-200.
26. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. *Cancer Res* 65: 6029-6033.
27. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, et al. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. *Cancer Res* 69: 7165-7169.
28. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, et al. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. *Proc Natl Acad Sci*.
29. Si ML, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor growth. *Oncogene* 26: 2799-2803.
30. Sarkar FH, Li Y, Wang Z, Kong D, Ali S (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. *Drug Resist Updat* 13: 57-66.
31. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. *Curr Biol* 17: 1298-1307.
32. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. *Biochem Biophys Res Commun* 377: 114-119.
33. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. *Cell Death Differ* 17: 236-245.
34. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. *Oncogene* 26: 5017-5022.
35. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. *Proc Natl Acad Sci* 105: 13421-13426.
36. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). *J Biol Chem* 282: 14328-14336.
37. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, et al. (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR 21 in breast cancer cells. *J Biol Chem* 283: 1026-1033.
38. Qi L, Bart J, Tan LP, Platteel I, Sluis Tv, et al. (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in fl at epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. *BMC Cancer* 9: 163.
39. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. *Cell Res* 18: 350-359.
40. Song B, Wang C, Liu J, Wang X, Lv L, et al. (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. *Exp Clin Cancer Res* 29: 29.
41. Fix LN, Shah M, Efferth T, Farwell MA, Zhang B (2010) MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. *Cancer Genomics Proteomics*. 7: 261-277.
42. Braun J, Hüttelmaier S (2011) Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. *Thyroid Res* 4: S1.
43. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol* 12: 247-256.
44. Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, et al. (2012) Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. *BMC Cancer* 12: 29.
45. Wang C, Zheng X, Shen C, Shi Y (2012) MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. *J Exp Clin Cancer Res* 31: 58.
46. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci* 102: 13944-13949.
47. Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, et al. (2009) Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. *Biol Cell* 101: 511-524.
48. Liu Q, Fu H, Sun F, Zhang H, Tie Y, et al. (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. *Nucleic Acids Res* 36: 5391-5404.
49. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, et al. (2012) Downregulation of the tumor-suppressor miR-16 via progesterin-mediated oncogenic signaling contributes to breast cancer development. *Breast Cancer Res* 14: R77.
50. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG et al. (2010) Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. *Cancer Res* 70: 7176-7186.
51. Yahya SM, Elsayed GH (2015) A summary for molecular regulations of miRNAs in breast cancer. *Clin Biochem* 48: 388-96.
52. Pasquier J, Magal P, Boulange-Lecomte C, Webb G, Le Foll F (2011) Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population Dynamics model. *Biol Direct* 6: 5.
53. Yu DD, Lv MM, Chen WX, Zhong SL, Zhang XH, et al. (2015) Role of miR-155 in drug resistance of breast cancer. *Tumor Biol* 36: 1395-1401.
54. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter mediated multidrug resistance in cancer cells: evaluation of current strategies. *Curr Mol Pharmacol* 1: 93-105.
55. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, et al. (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. *Proc Natl Acad Sci* 104: 13513-13518.
56. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, et al. (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. *Biochem Pharmacol* 76: 582-8.

57. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. *J Biol Chem* 283: 31079-86.
58. Palakurthi S, Yellepeddi VK, Vangara KK (2012) Recent trends in cancer drug resistance reversal strategies using nanoparticles. *Expert Opin Drug Deliv* 9: 287-301.
59. Zhao ZL, Cai Y, Wang YY, Xia CL, Li CX, et al. (2015) Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 44: 400-9.
60. Kars MD, Iseri OD, Gündüz U, Ural AU, Arpacı F, et al. (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. *Anticancer Res* 26: 4559-4568.
61. Lu L, Ju F, Zhao H, Ma X (2015) MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABC1. *Biotechnol Lett* 37: 2387-94.
62. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther* 7: 2152-9.
63. Chen J, Tian W, Cai H, He H, Deng Y (2012) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. *Medical Oncology* 29: 2527-2534.
64. Zhang HD, Sun DW, Mao L, Zhang J, Jiang LH, et al. (2015) MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. *Biochem Biophys Res Commun* 465: 702-13.
65. Xu X, Lv YG, Yan CY, Yi J, Ling R (2016) Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. *Biochem Biophys Res Commun* pii: S0006-291X(16)31554-6.
66. Wang Y, Zhao L, Xiao Q, Jiang L, He M, et al. (2016) miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. *Gynecol Oncol* 141: 592-601.
67. Shen H, Li L, Yang S, Wang D, Zhong S, et al. (2016) MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3 $\beta$  signaling pathway. *Gene* 593: 84-90.
68. Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB, et al. (2015) Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. *BMC Cancer* 15: 540.
69. Shen R, Wang Y, Wang CX, Yin M, Liu HL, et al. (2015) MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. *Am J Transl Res* 7: 2115-26.
70. Long J, Ji Z, Jiang K, Wang Z, Meng G (2015) miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1. *Biomed Res Int*.
71. Xie X, Hu Y, Xu L, Fu Y, Tu J, et al. (2015) The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. *Tumour Biol* 36: 7185-7194.
72. Chen X, Wang YW, Xing AY, Xiang S, Shi DB, et al. (2016) Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. *J Pathol* 239: 459-472.
73. Gu X, Li JY, Guo J, Li PS, Zhang WH (2015) Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line. *Med Sci Monit* 21: 3291-3297.
74. Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang LK, et al. (2015) miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. *Oncol Rep* 33: 2504-2512.
75. Zhang AX, Lu FQ, Yang YP, Ren XY, Li ZF, et al. (2015) MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. *Cell Biol Int*.
76. Zheng Y, Lv X, Wang X, Wang B, Shao X, et al. (2016) MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. *Oncol Rep* 35: 683-690.
77. Zhang Y, Wang Y, Wei Y, Li M, Yu S, et al. (2015) MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition. *Sci Rep* 5: 15424.
78. Cui J, Yang Y, Li H, Leng Y, Qian K, et al. (2015) MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. *Oncogene* 34: 4018.
79. Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, et al. (2015) MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. *Oncotarget* 6: 3268-3279.
80. Hu Y, Xu K, Yague E (2015) miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. *Breast Cancer Res Treat* 151: 269-280.
81. Yuan Y, Yao YF, Hu SN, Gao J, Zhang LL (2015) MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2. *PLoS One* 10: e0129843.
82. Feng X, Zhao L, Gao S, Song X, Dong W, et al. (2016) Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. *Gene* 578: 232-241.
83. Zhang X, Zhong S, Xu Y, Yu D, Ma T, et al. (2016) MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3beta/beta-Catenin Signaling Pathway. *PLoS One* 11: e0153194.
84. Ma MT, He M, Wang Y, Jiao XY, Zhao L, et al. (2013) MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting cancer resistance protein (BCRP/ABCG2). *Cancer Lett* 339: 107-115.
85. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem* 283: 29897-29903.
86. Liang Z, Wu H, Xia J, Li Y, Zhang Y, et al. (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol* 79: 817-824.
87. Kovalchuk O, Zemp FJ, Filkowski JN, Altamirano AM, Dickey JS, et al. (2010) microRNAome changes in bystander three-dimensional human tissue models suggest priming of apoptotic pathways. *Carcinogenesis* 31: 1882-1888.
88. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent SMANCS. *Cancer Res* 46: 6387-6392.
89. Gelperina S, Kisich K, Iseman MD, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. *Am J Respir Crit Care Med* 172: 1487-1490.
90. De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine* 3: 133-149.
91. Provenzale JM, Silva GA (2009) Uses of nanoparticles for central nervous system imaging and therapy. *AJNR Am J Neuroradiol* 30: 1293-1301.
92. Wang H, Chen X (2009) Applications for site-directed molecular imaging agents coupled with drug delivery potential. *Expert Opin Drug Deliv* 6: 745-768.
93. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V (2005) Iron oxide nanoparticles for sustained delivery of anticancer agents. *Mol Pharm* 2: 194-205.
94. Gao X, Chen JC, Wu Q, Chen GQ (2011) Polyhydroxyalkanoates as a source of chemicals, polymers, and biofuels. *Curr Opin Biotechnol*. 22: 768-774.
95. Verlinden RA, Hill DJ, Kenward MA, Williams CD, Radecka I (2007) Bacterial synthesis of biodegradable polyhydroxyalkanoates. *J Appl Microbiol* 102: 1437-1449.
96. Yalçın S, Khodadust R, Ünsoy G, Garip CI, Mumcuoglu DZ, et al. (2015) Synthesis and characterization of Poly-hydroxybutyrate (PHB) coated magnetic nanoparticles: toxicity analyses on different cell lines. *Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry* 45: 700-708.
97. Davies OR, Head L, Armitage D, Pearson EA, Davies MC, et al. (2008) Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery. *Langmuir* 24(14): 7138-46.
98. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. *Cell* 120: 635-647.
99. Stahlhut Espinosa CE, Slack FJ (2006) The role of microRNAs in cancer. *Yale J Biol Med* 79: 131-140.
100. Shen H, Sun T, Ferrari M (2012) Nanovector delivery of siRNA for cancer therapy. *Cancer Gene Ther* 19: 367-373.

101. Takahashi K, Yan I, Wen HJ, Patel T (2013) microRNAs in liver disease: from diagnostics to therapeutics. *Clin Biochem* 46: 946-952.
102. Devulapally R, Sekar NM, Sekar TV, Foygel K, Massoud TF, et al. (2015) Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy. *ACS Nano* 9: 2290-2302.
103. Wang H, Jiang Y, Peng H, Chen Y, Zhu P et al. (2015) Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. *Adv Drug Deliv Rev* 81: 142-160.
104. Yuba E, Kojima C, Sakaguchi N, Harada A, Koiwai K, et al. (2008) Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes. *J Control Release* 130(1): 77-83.
105. Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J, et al. (2014) Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. *Mol Can Ther* 13: 2352-2360.
106. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK et al. (2011) MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. *Cancer research* 71: 5214-5224.
107. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. *Nat Med* 17: 211-215.
108. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, et al. (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. *Mol Ther* 19: 1116-1122.
109. Jin H, Tuo W, Lian H, Liu Q, Zhu XQ, et al. (2010) Strategies to identify microRNA targets: new advances. *N Biotechnol* 27: 734-738.
110. Tekie FS, Atyabi F, Soleimani M, Arefian E, Atashi A, et al. (2015) Chitosan polyplex nanoparticle vector for miR-145 expression in MCF-7: Optimization by design of experiment. *Int J Biol Macromol* 81: 828-837.
111. Geng Y, Lin D, Shao L, Yan F, Ju H (2013) Cellular delivery of quantum dot-bound hybridization probe for detection of intracellular pre-microRNA using chitosan/poly( $\gamma$ -lutamic acid) complex as a carrier. *PLoS One* 8: e65540.
112. Zhi F, Dong H, Jia X, Guo W, Lu H, et al. (2013) Functionalized graphene oxide mediated adriamycin delivery and miR21 gene silencing to overcome tumor multidrug resistance in vitro. *PLoS One* 8: e60034.
113. Bhargava-Shah A, Foygel K, Devulapally R, Paulmurugan R (2016) Orlistat and antisense-miRNA-loaded PLGA PEG nanoparticles for enhanced triple negative breast cancer therapy. *Nanomedicine* 11: 235-247.
114. Muthiah M, Islam MA, Lee HJ, Moon MJ, Cho CS, et al. (2015) MicroRNA delivery with osmotic polysorbitol-based transporters suppresses breast cancer cell proliferation. *International Journal of Biological Macromolecules* 72: 1237-1243.
115. Deng X, Cao M, Zhang J, Hu K, Yin Z, et al. (2014) Hyaluronic acid-chitosan nanoparticles for codelivery of miR34a and doxorubicin in therapy against triple-negative breast cancer. *Biomaterials* 35: 4333-4344.
116. Bhattacharya S, Ahir M, Patra P, Mukherjee S, Ghosh S, et al. (2015) PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. *Biomaterials* 51: 91-107.
117. Wang S, Zhang J, Wang Y, Chen M (2016) Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542 3p for triple-negative breast cancer therapy. *Nanomedicine* 12: 411-420.
118. Ekin A, Karatas OF, Culha M, Ozen M (2014) Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. *J Gene Med* 16: 331-335.
119. Hayward SL, Francis DM, Kholmatov P, Kidambi S (2016) Targeted Delivery of MicroRNA125a-5p by Engineered Lipid Nanoparticles for the Treatment of HER2 Positive Metastatic Breast Cancer. *J Biomed Nanotechnol* 12: 554-568.
120. Jin H, Yu Y, Chrisler WB, Xiong Y, Hu D, et al. (2012) Delivery of MicroRNA-10b with Polylysine Nanoparticles for Inhibition of Breast Cancer Cell Wound Healing. *Breast Cancer* 6: 9-19.
121. Sekar TV, Devulapally R, Sekar NM (2015) Polymer nanoparticles mediated codelivery of anti-miR-10b and anti-miR z1 for achieving triple negative breast cancer therapy.
122. Yoo B, Kavishwar A, Ross A, Wang P, Tabassum DP, et al. (2015) Combining miR-10b-Targeted Nanotherapy with Low Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. *Cancer Res* 75: 4407-4415.
123. Yi H, Liu L, Sheng N, Li P, Pan H, et al. (2016) Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells. *Biomacromolecules* 17: 1737-1747.
124. Yu Y, Yao Y, Yan H, Wang R, Zhang Z, et al. (2016) A Tumor-specific MicroRNA Recognition System Facilitates the Accurate Targeting to Tumor Cells by Magnetic Nanoparticles. *Mol Ther Nucleic Acids* 5: e318.
125. Wang S, Cao M, Deng X, Xiao X, Yin Z, et al. (2014) Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. *Adv Healthc Mater* 4: 281-290.
126. Tyagi N, Arora S, Deshmukh SK, Singh S, Marimuthu S, et al. (2016) Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics. *J Biomed Nanotechnol* 12: 28-42.